These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31449347)

  • 1. Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model.
    Xu H; Muise ES; Javaid S; Chen L; Cristescu R; Mansueto MS; Follmer N; Cho J; Kerr K; Altura R; Machacek M; Nicholson B; Addona G; Kariv I; Chen H
    J Cell Mol Med; 2019 Oct; 23(10):7063-7077. PubMed ID: 31449347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
    Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
    Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
    Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
    Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
    J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
    Bhise NS; Elsayed AH; Cao X; Pounds S; Lamba JK
    Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 31022985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.
    Lueck SC; Russ AC; Botzenhardt U; Schlenk RF; Zobel K; Deshayes K; Vucic D; Döhner H; Döhner K; Fulda S; Bullinger L
    Oncotarget; 2016 Aug; 7(31):49539-49551. PubMed ID: 27385100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
    Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
    Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
    Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
    PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications.
    Chen F; Wu X; Niculite C; Gilca M; Petrusca D; Rogozea A; Rice S; Guo B; Griffin S; Calin GA; Boswell HS; Konig H
    J Cell Mol Med; 2020 Jul; 24(13):7378-7392. PubMed ID: 32450611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
    Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
    Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia.
    Kuett A; Rieger C; Perathoner D; Herold T; Wagner M; Sironi S; Sotlar K; Horny HP; Deniffel C; Drolle H; Fiegl M
    Sci Rep; 2015 Dec; 5():18411. PubMed ID: 26674118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia.
    Sun H; Ren Y; Zhou X; Chen Q; Liu Y; Zhu C; Ruan Y; Ruan H; Tong H; Ying S; Lin P
    Technol Cancer Res Treat; 2023; 22():15330338231207765. PubMed ID: 37872685
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
    Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
    Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia.
    Allen B; Savoy L; Ryabinin P; Bottomly D; Chen R; Goff B; Wang A; McWeeney SK; Zhang H
    Br J Haematol; 2024 Jul; 205(1):207-219. PubMed ID: 38867543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
    Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
    Lamba JK; Pounds S; Cao X; Crews KR; Cogle CR; Bhise N; Raimondi SC; Downing JR; Baker SD; Ribeiro RC; Rubnitz JE
    Leuk Lymphoma; 2016; 57(4):909-20. PubMed ID: 26366682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
    Tanaka M
    Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.